Physician profile
James Blanchfield
NPI 1538163944
$685.69
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $38.91 · 2020: $25.23 · 2023: $291 · 2024: $331.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $622.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $621.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $184.53 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $86.14 | 2019-2024 | Rybelsus, Ozempic |
| Abbvie INC. | $65.48 | 2023 | Ubrelvy, Vraylar, Qulipta |
| Merck Sharp & Dohme LLC | $59.61 | 2024 | Gardasil, Gardasil 9, Capvaxive |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.00 | 2023-2024 | Tradjenta, Synjardy, Jardiance |
| Pfizer INC. | $39.24 | 2019-2023 | |
| Astellas Pharma US INC | $33.54 | 2024 | Veozah |
| Amgen INC. | $25.13 | 2024 | Otezla, Repatha |
| Corcept Therapeutics | $23.12 | 2023 | Korlym |
| Abbott Laboratories | $23.02 | 2024 | Freestyle Libre 2 |
| Mannkind Corporation | $20.77 | 2024 | |
| Lundbeck LLC | $19.70 | 2024 | Rexulti |
| Exact Sciences Corporation | $18.52 | 2023 | Cologuard Collection Kit |
| Inspire Medical Systems, INC. | $15.30 | 2024 | Inspire |
| Astrazeneca Pharmaceuticals LP | $13.59 | 2024 | Airsupra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Blanchfield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.